On May 10, 2021 Kinnate Biopharma Inc. (Nasdaq: KNTE) ("Kinnate"), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, reported that data from pre-clinical studies of its RAF inhibitor candidate, KIN-2787, have been selected for a poster presentation at the 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Kinnate Biopharma, MAY 10, 2021, View Source [SID1234579597]). The ASCO (Free ASCO Whitepaper) meeting will be held virtually from June 4-8, 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As we advance towards the initiation of clinical studies for our lead RAF inhibitor program, we are honored to be selected by the ASCO (Free ASCO Whitepaper) Scientific Program Committee to present findings from our pre-clinical studies of KIN-2787 at this year’s Annual Meeting," said Eric Murphy, Ph.D., co-founder and Chief Scientific Officer of Kinnate. "We are enthusiastic about the advancement of KIN-2787 to address actionable RAF mutations in molecular subtypes that are not addressed by existing drugs or are resistant to available standard-of-care therapies."
Oncogenic BRAF gene alterations, leading to aberrantly activated BRAF monomers (Class I mutations) or dimers (Class II and Class III mutations), are observed in approximately 6% of all human cancers. First-generation BRAF inhibitors targeting Class I BRAF mutants, including dabrafenib, encorafenib, and vemurafenib, provide significant clinical benefit to patients with BRAF V600 mutation-driven melanoma and select solid tumors as monotherapies or in combination with other targeted therapies. The currently approved BRAF inhibitors have not, however, proven to be effective in patients with Class II or III BRAF alterations. For example, approximately 62% of BRAF mutations in non-small-cell lung carcinoma (NSCLC) and approximately 21% of BRAF mutations in melanoma are identified as Class II and Class III BRAF mutations where the currently approved Class I inhibitors are not effective.
The data to be presented at the ASCO (Free ASCO Whitepaper) annual meeting were derived from pre-clinical studies evaluating the efficacy and tolerability of KIN-2787 in vitro and in vivo in BRAF mutation-driven human cancer models. A phase 1 dose escalation and expansion clinical trial evaluating the safety and efficacy of KIN-2787 monotherapy in patients with advanced or metastatic solid tumors harboring BRAF gene alterations, including Class II and III mutations, is expected to initiate in 2021.
Additional information on the ASCO (Free ASCO Whitepaper) annual meeting can be found online at: View Source Per ASCO (Free ASCO Whitepaper)’s Embargo & Release Information, complete abstracts will be released to the public on ASCO (Free ASCO Whitepaper)’s Meeting Library, View Source, at 5:00 p.m. ET on May 19, 2021.
Kinnate’s poster presentation will become available for on-demand viewing beginning Friday, June 4, 2021 at 9:00 a.m. ET, and can be accessed at: View Source